Non-specific immune activation

Immune system – broad, non-specific activation refers to a therapeutic approach aimed at stimulating the body's overall immune response rather than targeting a specific antigen or molecular pathway (NCI Dictionary). This strategy typically involves the use of immunostimulants or biological response modifiers, such as cytokines (e.g., interferons, interleukins) or microbial products (e.g., BCG), to enhance the activity of innate immune cells like macrophages and natural killer cells (StatPearls, NBK538254). In oncology, this approach is used to overcome tumor-induced immunosuppression and promote a general anti-tumor environment (Nature Reviews Drug Discovery, 2017). These agents work by mimicking signals of infection or cellular stress, thereby lowering the threshold for immune cell activation across the entire system. While historically significant, this method lacks the precision of modern targeted therapies like monoclonal antibodies or CAR-T cells. Because the activation is non-specific, it often leads to systemic side effects, including cytokine release syndrome and potential autoimmune manifestations. Notable examples of drugs in this category include Imiquimod for skin lesions and BCG for bladder cancer. Modern drug development has largely shifted from these broad approaches toward more targeted immunotherapies to improve the benefit-to-risk ratio.

Other names

Non-specific immunotherapyGeneral immune stimulationImmunostimulationBiological response modificationNon-specific immune response

Broad activation of the innate and adaptive immune systems through the stimulation of pattern recognition receptors (PRRs) such as Toll-like receptors, or the administration of exogenous cytokines to enhance general surveillance and effector functions (StatPearls, NBK538254).